Bellicum Phamaceuticals, Inc.
https://www.bellicum.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bellicum Phamaceuticals, Inc.
Trials In Focus: Joint Venture Aims To Simplify Cell Therapy Trials For Smaller Players
CTMC CEO Jason Bock talked to Scrip about the venture between MD Anderson and National Resilience, which provides manufacturing, process development and regulatory support for small cell therapy developers’ preclinical and clinical proof-of-concept studies. Meanwhile, Verge Genomics initiated a Phase Ib study of its AI-discovered drug for ALS; EyePoint and Aviceda dosed patients in their Phase II DME trials; Parexel teamed up with a non-profit cancer research group in Japan; and BARDA selected PPD to run its Phase II platform trial for ARDS.
Bellicum Weighs Options After Hitting Brakes On CAR-T Program
An analyst suggested the company might end up selling its technology to a large pharma player, citing AstraZeneca’s $68m buyout of LogicBio in October as a precedent.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
J.P. Morgan Extras: Pandemic Impact on Launch, Production, Development And More
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice